Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy
NCT ID: NCT01905969
Last Updated: 2015-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2012-10-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981
S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer
NCT00182611
Randomized Phase II Trial Evaluating DFS in The Absence of an Adjuvant Component of Perioperative Chemotherapy in Patients With Gastric Cancer
NCT06942663
S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer
NCT00134095
A Randomized Phase III Study of Adjuvant Chemotherapy With or Without Chemo-radiotherapy in Patients With Local Advanced Gastric Cancer After D2 Resection.
NCT02648841
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Biomarker positive
NF-kB(+)/JNK(-) in curatively removed specimens
No interventions assigned to this group
Biomarker negative
NF-kB(-)/JNK(+) in curatively removed specimens
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Operated before November 2009.
* Stage Ib/II(except for T1, T3N0)/III.
* Received postoperative (R0) adjuvant chemotherapy (S-1).
* Not received postoperative (R0) adjuvant chemotherapy (surgery alone).
* Signed informed consent to provide paraffin embedded tissue of removed specimens.
Exclusion Criteria
* Paraffin embedded tissue is not available.
* Unknown S-1 treatment condition.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iwate Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Satoshi Nishizuka
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Iwate Medical University School of Medicine
Morioka, Iwate, Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ishida K, Nishizuka SS, Chiba T, Ikeda M, Kume K, Endo F, Katagiri H, Matsuo T, Noda H, Iwaya T, Yamada N, Fujiwara H, Takahashi M, Itabashi T, Uesugi N, Maesawa C, Tamura G, Sugai T, Otsuka K, Koeda K, Wakabayashi G. Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers. PLoS One. 2012;7(8):e43236. doi: 10.1371/journal.pone.0043236. Epub 2012 Aug 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIAST-NJBMR-12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.